Table 1.
Patient characteristics
| Variable | Patients (n = 47) |
|---|---|
| Age (years) (median; IQR) | 59 (51–66) |
| Clinical tumor size (mm) (median; IQR) | 19 (13–28.5) |
| Clinical tumor stage (%) | |
| T1 | 25 (53.2) |
| T2 | 21 (44.7) |
| T3 | 1 (2.1) |
| Tumor type (%) | |
| Ductal | 34 (72.3) |
| Lobular | 7 (14.9) |
| Mixed ductal and lobular | 3 (6.4) |
| Other* | 3 (6.4) |
| Tumor grade (%) | |
| 1 | 14 (29.8) |
| 2 | 27 (48.9) |
| 3 | 10 (21.3) |
| Receptor status (%) | |
| ER+HER2- | 38 (80.9) |
| ER+HER2+ | 4 (8.5) |
| ER-HER2+ | 1 (2.1) |
| Triple negative | 4 (8.5) |
| Breast surgery (%) | |
| Breast-conserving surgery | 25 (53.2) |
| Mastectomy | 22 (46.8) |
| Axillary surgery (%) | |
| SLNB | 43 (91.5) |
| ALND | 4 (8.5) |
Abbreviations: IQR, interquartile range; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection
*Other tumor types: adenoid cystic carcinoma, mucinous carcinoma, encapsulated papillary carcinoma